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Genetic Polymorphisms in Dopamine- and   
Serotonin-Related Genes and Treatment   
Responses to Risperidone and Perospirone 
 
 
 
We investigated the possible association between genetic polymorphisms in the dopamine 
receptor and serotonin transporter genes and the responses of schizophrenic patients treated 
with either risperidone or perospirone. The subjects comprised 27 patients with schizo-
phrenia who were clinically evaluated both before and after treatment. The genotyping of 
the polymorphisms of the dopamine D2 receptor gene (DRD2) (rs1801028 and rs6277), the 
dopamine D4 receptor gene (DRD4) (120-bp tandem repeats and rs1800955), and serotonin 
transporter gene (5HTT)(variable number of tandem repeats; VNTR) were performed using 
the real-time polymerase chain reaction and sequencing. In DRD2 and 5HTT-VNTR, there 
were no significant correlations between clinical response and polymorphism in the case of 
risperidone, and for perospirone treatment it was impossible to analyze the clinical evalua-
tion due to the absence of genotype information. On the other hand, in DRD4 there were signi-
ficant correlations in the two-factor interaction effect on the Positive and Negative Syndrome 
Scale (PANSS) between the two drugs [120-bp tandem repeat, p=0.003; rs1800955, p=0.043]. 
Although the small sample represents a serious limitation, these results suggest that variants 
in DRD4 are a predictor of whether treatment will be more effective with risperidone or 
with perospirone in individual patients. 
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Introduction 
 
Scores of antipsychotic drugs for treating schizophrenia are available, but it is
difficult to anticipate which will the most effective in a particular patient because of 
the lack of biological indicators for their efficacies or the incidence rates of adverse
effects. Several studies have investigated the effects of genetic polymorphisms on
predicting treatment responses and the incidence of adverse effects. For the response
to risperidone treatment, Xing et al.
1 investigated 6 genetic polymorphisms in the do-
pamine D2 receptor gene (DRD2) in 125 Chinese schizophrenic patients. They re-
ported that the A allele in the DRD2 A-241G single-nucleotide polymorphism (SNP)
was associated with a higher risperidone efficacy. In addition, Wang et al.
2 showed 
that an allele of the serotonin transporter gene (5HTT) reversing lipid transport (RLT)
polymorphism may be a good predictor for a better outcome of risperidone treat-
ment. However, Xuan et al.
3 found that none of 8 SNPs in the dopamine D3 receptor 
gene (DRD3) were predictive in 130 schizophrenic patients taking only risperidone.
The above studies are limited by only risperidone being considered, and hence the 
indicated genetic variants might be predictors for treatments with other drugs. 
To assess which antipsychotic drug will be useful for a patient carrying a certain
genetic variation, it is important to determine simultaneously which of several drugs  
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are effective in numerous patients. Dolzan et al.
4 investi-
gated the effects of DRD1 A-48G, DRD2 Ins -141C Del, 
and DRD2 Ser 311 Cys variants on medical treatments of 
schizophrenia by risperidone, haloperidol, fluphenazine, 
or zuclopenthixole, and found no variations in the treat-
ment response or the incidence of adverse effects. There 
are numerous positive and negative data on genetic varia-
tions in schizophrenia, and so the present study aimed to 
clarify these inconsistencies. The Schizophrenia Research 
Forum database (http://www.schizophreniaforum.org/)5 
contains meta-analyzed data of all investigated variants 
published in peer-reviewed journals. Although the three 
variants investigated by Dolzan et al. are becoming ac-
cepted in genetic researches of schizophrenia, no indivi-
dual variant is supported by the Schizophrenia Research 
Forum meta-analysis. 
Our aim was to develop a reliable method for select-
ing antipsychotic drugs in individual patients. To this end, 
the involvement of genetic variations supported by the 
meta-analysis were studied for treatments by two sero-
tonin/dopamine antipsychotic drugs: risperidone and pe-
rospirone. Perospirone is an antipsychotic drug that was 
developed in Japan;6 the profile of its receptor binding 
activity classifies it as a serotonin/dopamine antagonist 
(SDA).
7 This agent is a 5-HT1A partial agonist and ex-
hibits a higher efficacy in the treatment of anxiety
8 and a 
lower incidence of hyperprolactinemia than risperidone.
9 
Although both drugs are classified as SDAs, it is suspect-
ed that they exhibit different affinities for dopaminergic 
and serotoninergic receptors that may underlie clinical 
variations in their efficacies or in the incidence rates of 
adverse effects. We therefore searched all of the genetic 
variants that were significantly supported by the Schizo-
phrenia Database on Dopamine and Serotonin-Related 
Genes. The found variants were rs1801028 and rs6277 
in DRD2, a 120-bp tandem repeats (TR) and rs1800955 
in DRD4, and a 17-bp variable number of tandem repeats 
(VNTR) in 5HTT, and all of these were investigated in 
this study. 
 
Methods 
 
The subjects were recruited from the cohort of patients 
who were treated in four Kansai medical organizations: 
Osaka Medical College, Kansai Medical College, Nara 
Medical University, and Wakayama Medical University. 
Other associated hospitals also cooperated in this study. 
All of the subjects were diagnosed as schizophrenic ac-
cording to the International Classification of Diseases-
10 (ICD-10) criteria by two trained psychiatrists, and 
informed consent was obtained from each subject. Each 
subject was randomly assigned to receive either risperi-
done or perospirone treatment. The drugs were allocated 
in a randomized double-blind manner. The Positive and 
Negative Syndrome Scale (PANSS) and the Drug-Induc-
ed Extrapyramidal Symptoms Scale (DIEPSS) were used 
for the clinical evaluation. The maximum treatment period 
was 3 months. It was possible to collect the clinical changes 
according to PANSS and DIEPSS from only 27 of the 39 
patients who were originally enrolled in the study. This 
study was approved by the ethical committees at the four 
participating organizations and other associated hospitals. 
The entire study was conducted by the “Kansai four me-
dical organizations”, and the human rights of each partici-
pant were maintained throughout the treatment courses. 
Each genomic variant was analyzed by the following 
methods: DNA sequencing for the 17-bp TR in the 5HTT 
gene, the restriction fragment length polymorphism (RF-
LP) polymerase chain reaction (PCR) method for the 120-
bp TR, and the fluorescence resonance energy transfer 
(FRET) PCR method for the other three SNPs (rs1801028 
and rs6277 in DRD2, and rs1800955 in DRD4). Experi-
mental data from the analysis of each variant are reported 
in Table 1. Two-way analysis of variance was used to an-
alyze the data (using SPSS, ver. 13). 
 
Results 
 
The mean age of the 27 participants who were clinically 
assessed was 37.0 years, and 55.6% were male. The in-
dividual DNA samples were analyzed for Hardy-Weinberg 
equilibrium, and none of the individual markers of the 
five variants deviated significantly from the expected fre-
quencies. Overall, the response as assessed by the PANSS 
did not differ significantly between risperidone and pe-
rospirone treatments (p=0.655). The results for each var-
TABLE 1. Genotyping details for single-nucleotide polymorphisms (SNPs) investigated in the DRD2, DRD4, and 5HTT genes 
Gene  Polymorphism  Forward primer  Reverse primer 
DRD2 rs1801028  TTCTTCTCTGGTTTGGCGG GCTGGAGATGGAGATGCT 
 rs6277 GGAGCTGGAGATGGAGATG  CAATCTTGGGGTGGTCTTT 
DRD4 120-bp  TR  GGTTGTCTGTCTTTTCTCATTG GTTAAAGGGAGAAATGAGGACT 
 rs1800955  GGGATGAGCTAGGCGTCG  ACCCTAGTCCACCTGGTA 
5HTT VNTR  Sequenced  Sequenced 
DRD2: dopamine D2 receptor gene, DRD4: dopamine D4 receptor gene, 5HTT: serotonin transporter gene, TR: tandem repeat, VNTR:
variable number of tandem repeats      
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iant are presented in Table 2. 
 
D2 receptor gene (rs1801028, rs6277) 
For the rs1801028 polymorphism, it was impossible 
to analyze the clinical evaluation with perospirone due to 
the absence of the A/G or A/A genotype within the pe-
rospirone-treated group. The change in the PANSS score 
in patients treated by risperidone did not differ signifi-
cantly between A/G and G/G genotypes. A similar ten-
dency was found for the analysis of rs6277, with all of 
the samples treated with perospirone being categorized 
as the C/C genotype. The PANSS score did not differ sig-
nificantly between C/C and C/T genotypes among patients 
who received risperidone. For the investigated DRD2 
polymorphisms, it was almost impossible to predict the 
clinical response to risperidone treatment. 
D4 receptor gene (120-bp tandem repeat,  
rs1800955) 
For the 120-bp TR, a two-factor interaction effect in 
the PANSS score was found to be significant between the 
two drugs (p=0.003, Figure 1). A significantly different 
two-factor interaction was also observed for rs1800955 
(p=0.043, Figure 1) between the groups treated with pe-
rospirone and risperidone. 
 
5HTT -variable number of tandem repeats 
The clinical response to perospirone treatment tended 
to be better in 10/10 genotypes than 12/12 genotypes (10 
and 12 referring to the number of base pairs repeated in 
the VNTR), but this difference was not statistically sig-
nificant. The clinical response in the risperidone group did 
not vary with the genotype. An evaluation of genotype dif-
TABLE 2. Allele frequencies for SNPs in the DRD2, DRD4, and 5HTT genes under perospirone and risperidone treatments   
DRD2 rs1801028  A/A  A/G  G/G 
 Perospirone  -  -  12 
 Risperidone  -  4  11 
 rs6277  C/C  C/T  T/T 
 Perospirone  12  -  - 
 Risperidone  12  3  - 
DRD4 120-bp  TR  R1/R1  R1/R2  R2/R2 
 Perospirone  01 5  06 
 Risperidone  -  4  11 
 rs1800955  C/C  C/T  T/T 
 Perospirone  -  2  10 
 Risperidone  -  4  11 
5HTT VNTR  R10/R10  R10/R12  R12/R12 
 Perospirone  -  4  08 
 Risperidone  -  3  12 
Numbers in the table represent the number of patients. DRD2: dopamine D2 receptor gene, DRD4: dopamine D4 receptor gene, 5HTT:
serotonin transporter gene, TR: tandem repeat, VNTR: variable number of tandem repeats   
 
FIGURE 1. DRD4 120-bpTR: Within R1/ 
R2 genotyped samples: risperidone vs. 
perospirone [F (1.22)=8.41, p=0.008]. 
Within perospirone-treated group: R1/ 
R2 vs. R2/R2 [F (1,22)=11.85, p=0.002].
DRD4 rs1800955: Within perospirone-
treated group: C/T vs T/T [F (1,23)=8.99,
p=0.006]. DRD4: dopamine D4 gene, 
PANSS: Positive and Negative Syn-
drome Scale, TR: tandem repeat.   
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ferences between the two agents also found no significant 
correlation. 
 
Discussion 
 
This study has limitations in terms of the small sample 
and the absence of validation tests for the blood con-
centrations of the investigated drugs. Also, the statistical 
analysis was not completed for several variants due to the 
small number of observations, and hence the presented 
results should be interpreted with caution. Within the in-
vestigated five variants, only the 120-bp TR and rs1800955 
were possible predictors of the clinical response to ris-
peridone or perospirone. For the 120-bp TR and rs180095 
in DRD4 there were clinical differences in the PANSS 
score between the two drugs. Patients with the 120-bp TR 
tended to respond well to risperidone especially in terms 
of the PANSS score for positive symptoms, whereas those 
with rs180095 tended to respond well to perospirone es-
pecially in terms of the PANSS anxiety score. Based on 
PANSS scores, it is strongly suggested that patients with 
the R1/R2 genotype (the combination of one repeat of 120-
bp with two repeats of 120-bp) on the 120-bp TR should 
receive risperidone, and patients with the C/T genotype on 
rs1800955 should receive perospirone. Both the 120-bp TR 
and rs1800955 are reportedly related to the risk of schizo-
phrenia onset, and a meta-analysis positively supported the 
results for the variants described herein.
5 Located in the 
promoter region of the DRD4 gene, these variants appear 
in different haplotype blocks.
10 In addition, the longer al-
lele of the 120-bp TR and the T allele on rs1800955 de-
crease the DRD4 messenger RNA (mRNA) expression,
11,12 
so these variants are regarded to be genetically functional. 
A genetic study of schizophrenia found an association with 
the longer allele on the DRD4 gene, whereas the rs1800955 
C allele-which may lead to higher expression of DRD4 
mRNA-was associated with schizophrenia. Therefore, how 
the alteration of DRD4 expression relates to the etiology 
of schizophrenia remains controversial. In a postmortem 
study of schizophrenic brains, the expression of DRD4 
mRNA was found to be three times higher in the prefron-
tal cortex.
13 However, risperidone and haloperidol are 
known to increase the expression of DRD4,
14 so further 
studies are needed to reveal those alterations in mRNA ex-
pression that are related to the pathogenesis of schizophre-
nia or the effect of antipsychotic agents. 
Thus, we aimed to develop reliable criteria for choos-
ing risperidone or perospirone for the treatment of schi-
zophrenia according to the genetic characteristic of indi-
vidual patients. As for the choice of different SDAs, al-
though the small number of analyzed samples prevented 
us from determining whether the treatment efficacies of 
the two antipsychotics are influenced by the DRD4 geno-
type, our results suggest that an individual with the R1/R2 
120-bp TR DRD4 genotype should be treated with ris-
peridone, whereas one with the C/T genotype on rs1800955 
in DRD4 should receive perospirone. Both of the geno-
types (R1/R2 in the 120-bp TR, and C/T in rs1800955) 
indicative of perospirone treatment are known to increase 
the risk of schizophrenia. Future studies should investigate 
how perospirone regulates DRD4 in order to clarify the 
pathophysiological involvement of DRD4. 
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